Federated Hermes Inc. Reduces Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Federated Hermes Inc. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 22.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,081 shares of the specialty pharmaceutical company’s stock after selling 14,585 shares during the quarter. Federated Hermes Inc.’s holdings in Supernus Pharmaceuticals were worth $1,449,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 96.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 687 shares during the period. Covestor Ltd lifted its holdings in Supernus Pharmaceuticals by 115.0% during the 3rd quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 1,257 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at about $262,000. Profund Advisors LLC grew its stake in Supernus Pharmaceuticals by 17.7% in the 3rd quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 1,454 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Supernus Pharmaceuticals by 28.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 2,203 shares in the last quarter.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 3,884 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total transaction of $128,133.16. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $282,724.30. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, VP Padmanabh P. Bhatt sold 12,364 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,884 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total value of $128,133.16. Following the completion of the transaction, the vice president now owns 8,570 shares in the company, valued at approximately $282,724.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,739 shares of company stock worth $1,227,433. Corporate insiders own 8.76% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler decreased their price target on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th.

Supernus Pharmaceuticals Trading Up 1.8 %

Shares of SUPN stock opened at $30.60 on Tuesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $21.99 and a twelve month high of $38.09. The stock has a fifty day simple moving average of $31.56 and a two-hundred day simple moving average of $28.67.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The business had revenue of $164.30 million during the quarter, compared to analysts’ expectations of $155.03 million. Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The firm’s revenue was down 1.8% compared to the same quarter last year. During the same period last year, the company earned $0.43 earnings per share. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.